Comparative analysis of mAb interacting at mutation positions in RBD to understand neutralization efficacy
mAb Position B.1 BA.1 BA.4 / BA.5 BA.4.6 BA.2.75.2 BJ.1 BQ.1.1 Remarks
Casirivimab (single mAb) 486* V V S V Mutation at the position for BA.4/BA.5 (486V), BA.4.6(486V), BQ.1.1(486V) and BA.2.75.2(486S) strongly correlates with higher EC50 values (>10K indicating neutralization escape)
490 V
493* R R
496* S
EC50 (ng/ml) 21 1890 >50000 >50000 >50000 880 >50000
Imdevimab (single mAbs) 346 T T T T Mutation at the position for BA.1(446S), BQ.1.1(346T), BA.2.75.2 (446S & 346T), BJ.1 (446S & 346T) strongly correlates with higher EC50 values (>10K indicating neutralization escape). Mutation at position for BA.4.6 (346T) strongly correlates with higher EC50 values (1000-10K indicating poor neutralization)
444 T
445 P
446* S S S
EC50 (ng/ml) 19 >50000 994 2109 >50000 >50000 >50000
Cocktail mAbs EC50 (ng/ml) 9 3642 2611 5395 >50000 2456 >50000
Bamlanivimab (single mAb) 452 R R R No correlation established as all omicron sublineage show higher EC50 values (>10K indicating neutralization espcape)
482 S
483 A
486* V V S V
490 V
493* R R
EC50 (ng/ml) 16 >50000 >50000 >50000 >50000 >50000 >50000
Etesevimab (single mAb) 405 N N N N N No correlation established as all omicron sublineage show higher EC50 values (>10K indicating neutralization espcape)
408 S S S S S
460 K K
486* V V S V
490 V
493* R R
EC50 (ng/ml) 53 >50000 >50000 >50000 >50000 >50000 >50000
Cocktail mAbs EC50 (ng/ml) 18 >50000 >50000 >50000 >50000 >50000 >50000
Cilgavimab (single mAb) 346 T T T T Mutation at position for BA.4.6(346T), BA.2.75.2(346T), BJ.1(346T) and BQ.1.1(346T) strongly correlates with higher EC50 values (>10K indicating neutralization espcape)
444 T
445 P
446* S S S
452 R R R
490 V
493* R R
EC50 (ng/ml) 37 2658 88 24200 >50000 >50000 >50000
Tixagevimab (single mAb) 486* V V S V Mutation at position for BA.4/BA.5(486V), BA.4.6(486V), BQ.1.1(486V) and BA.2.75.2(486S) strongly correlates with higher EC50 values (>10K indicating neutralization espcape)
493* R R
EC50 (ng/ml) 7 173 10090 27740 >50000 304 >50000
Cocktail mAbs EC50 (ng/ml) 7 97 155 7131 >50000 482 >50000
Amubarvimab (single mAb) 460 K K Mutation at position for BA.2.75.2(460K) and BQ.1.1(460K) strongly correlates with higher EC50 values (>10K indicating neutralization escape)
486* V V S V
493* R R
EC50 (ng/ml) 53 5641 1234 1290 >50000 4762 >50000
Romlusevimab (single mAb) 339 D D D H H D Mutation at position for BA.4.6(346T), BA.2.75.2(346T), BJ.1(346T) and BQ.1.1(346T) strongly correlates with higher EC50 values (>10K indicating neutralization espcape)
346 T T T T
EC50 (ng/ml) 852 866 8279 >50000 >50000 >50000 >50000
Cocktail mAbs EC50 (ng/ml) 64 657 1819 1015 >50000 5359 >50000
Regdanvimab (single mAb) 452 R R R Mutation at position for BA.4/BA.5(486V), BA.4.6(486V), BQ.1.1(486V), BA.1(493R) and BJ.1(493R) strongly correlates with higher EC50 values (>10K indicating neutralization espcape).
486* V V S V
490 V
493* R R
496* S
EC50 (ng/ml) 7 >50000 >50000 >50000 6336 >50000 >50000
Bebtelovimab (single mAb) 346 T T T T One of the most effective mAb, but no clear correlation established against mutations for neutralisation escape
444 T
445 P
446* S S S
EC50 (ng/ml) 5 7 6 7 14 >50000 >50000
Sotrovimab (single mAb) 339 D D D H H D One of the most effective mAb. However, mutation at the position for BA.4.6 (339D and 346T) and BQ.1.1(339D, 346T and 444T) strongly correlates with higher EC50 values (>10K indicating neutralization escape)
346 T T T T
444 T
EC50 (ng/ml) 157 833 5554 13000 3239 825 >50000
Adintrevimab (single mAb) 405 N N N N N Mutation at the position for BA.4/BA.5 (405N and 408S), BA.4.6(405N and 408S), BA.2.75.2(405N and 408S), BJ.1(405N and 408S) and BQ.1.1(405N and 408S) strongly correlates with higher EC50 values (>10K indicating neutralization escape)
408 S S S S S
496* S
EC50 (ng/ml) 14 23 >50000 >50000 >50000 >50000 >50000
indicates an increase in EC50 of cocktail mAbs as compared to single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to single mAb. = indicates equal EC50 of cocktail mAbs as compared to single mAb. The first and second arrows indicate a relative change in EC50 of cocktail mAbs about each mAbs when used solitarily. indicates an increase in EC50 of cocktail mAbs as compared to single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to single mAb. = indicates equal EC50 of cocktail mAbs as compared to single mAb. The first and second arrows indicate a relative change in EC50 of cocktail mAbs about each mAbs when used solitarily. indicates an increase in EC50 of cocktail mAbs as compared to single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to single mAb. = indicates equal EC50 of cocktail mAbs as compared to single mAb. The first and second arrows indicate a relative change in EC50 of cocktail mAbs about each mAbs when used solitarily. indicates an increase in EC50 of cocktail mAbs as compared to single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to single mAb. = indicates equal EC50 of cocktail mAbs as compared to single mAb. The first and second arrows indicate a relative change in EC50 of cocktail mAbs about each mAbs when used solitarily. indicates an increase in EC50 of cocktail mAbs as compared to single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to single mAb. = indicates equal EC50 of cocktail mAbs as compared to single mAb. The first and second arrows indicate a relative change in EC50 of cocktail mAbs about each mAbs when used solitarily. indicates an increase in EC50 of cocktail mAbs as compared to single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to single mAb. = indicates equal EC50 of cocktail mAbs as compared to single mAb. The first and second arrows indicate a relative change in EC50 of cocktail mAbs about each mAbs when used solitarily. indicates an increase in EC50 of cocktail mAbs as compared to single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to single mAb. = indicates equal EC50 of cocktail mAbs as compared to single mAb. The first and second arrows indicate a relative change in EC50 of cocktail mAbs about each mAbs when used solitarily. indicates an increase in EC50 of cocktail mAbs as compared to single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to single mAb. = indicates equal EC50 of cocktail mAbs as compared to single mAb. The first and second arrows indicate a relative change in EC50 of cocktail mAbs about each mAbs when used solitarily. indicates an increase in EC50 of cocktail mAbs as compared to single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to single mAb. = indicates equal EC50 of cocktail mAbs as compared to single mAb. The first and second arrows indicate a relative change in EC50 of cocktail mAbs about each mAbs when used solitarily. indicates an increase in EC50 of cocktail mAbs as compared to single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to single mAb. = indicates equal EC50 of cocktail mAbs as compared to single mAb. The first and second arrows indicate a relative change in EC50 of cocktail mAbs about each mAbs when used solitarily.